Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jennifer Bolzenius"'
Autor:
Angela M Halstead, Chiraag D Kapadia, Jennifer Bolzenius, Clarence E Chu, Andrew Schriefer, Lukas D Wartman, Gregory R Bowman, Vivek K Arora
Publikováno v:
eLife, Vol 6 (2017)
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs). Analysis from TCGA raised the possibility that hyperactive PPAR signaling, either due to PPAR ga
Externí odkaz:
https://doaj.org/article/5e55d396266f41bb8f7c93bd06a58047
Autor:
Sharon L. Freshour, Bryan Fisk, Timothy Hung-Po Chen, Haolin Shen, Matthew Mosior, Catrina Fronick, Jennifer Bolzenius, Obi L. Griffith, Vivek Arora, Malachi Griffith
Publikováno v:
Cancer Research. 83:6-6
Bladder cancer is the tenth most common cancer worldwide, accounting for over 500,000 new cancer cases and 200,000 cancer-related deaths per year. Depending on the degree of muscle invasiveness and disease spread at the time of diagnosis, 5-year surv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1de388cb6b845426cfbb42e68696fc46
https://doi.org/10.1158/1538-7445.am2023-6
https://doi.org/10.1158/1538-7445.am2023-6
Autor:
Vivek K. Arora, Xinming Su, Jennifer K. Sehn, Yuji Sato, Christopher G. Maher, Jennifer Bolzenius, Abdallah M. Eteleeb
Publikováno v:
JCI Insight. 3
Immune checkpoint blockade (ICB) provides clinical benefit to a minority of patients with urothelial carcinoma (UC). The role of CD4+ T cells in ICB-induced antitumor activity is not well defined; however, CD4+ T cells are speculated to play a suppor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa2382b5f6e4f352d7a82f74df07a9e
https://doi.org/10.1172/jci.insight.121062
https://doi.org/10.1172/jci.insight.121062
Autor:
Obi L. Griffith, Malachi Griffith, Vivek K. Arora, Matthew Mosior, Bryan Fisk, Sharon Freshour, Jennifer Bolzenius
Publikováno v:
Cancer Genetics. 244:6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55f6298c3b5d7da22776446bceda7c9c
https://doi.org/10.1016/j.cancergen.2020.04.018
https://doi.org/10.1016/j.cancergen.2020.04.018
Autor:
Clarence E Chu, Vivek K. Arora, Andrew E. Schriefer, Angela M Halstead, Gregory R. Bowman, Chiraag D Kapadia, Jennifer Bolzenius, Lukas D. Wartman
Publikováno v:
eLife, Vol 6 (2017)
Bladder cancer is the sixth most common type of cancer in the United States. At the moment, treatment options for advanced bladder cancer are limited to chemotherapy and immunotherapy, both of which benefit only some patients. Many other types of can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d289442091abfd6faeb66d87a59340ff
https://doi.org/10.7554/elife.30862
https://doi.org/10.7554/elife.30862
Autor:
Lukas D. Wartman, Gregory R. Bowman, Chiraag D Kapadia, Jennifer Bolzenius, Clarence E Chu, Vivek K. Arora, Angela M Halstead, Andrew E. Schriefer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3e643bfd7e7fb82320e8b04272a9f45
https://doi.org/10.7554/elife.30862.019
https://doi.org/10.7554/elife.30862.019
